NCT04023110View on ClinicalTrials.gov

Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 9, 2019

Primary Completion Date

August 31, 2024

Study Completion Date

January 14, 2025

Conditions

CardiotoxicityRisk Factor, CardiovascularToxicity Due to ChemotherapyBreast CancerCardiomyopathiesHeart Failure

Interventions

DRUG

Carvedilol

Individually dosed carvedilol

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

American Heart Association

OTHER

lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT04023110 - Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab | Biotech Hunter | Biotech Hunter